CasNo.439081-18-2,Afatinib (BIBW 2992),(439081-18-2) Suppliers

0 Metric Ton	Negotiable

Min.Order :0 Metric Ton
Purity: 99%
Payment Terms : L/C,T/T,Other

Keywords

Afatinib (BIBW 2992) BIBW 2992 439081-18-2

Quick Details

Appearance:Off-white to white solid powder
Application: The drug is a kinase agonist that is indicated as monotherapy for EFGR and tyrosine kinase suppressor-naive adult patients whose NSCLC is metastatic or locally advanced and the tumours are resistant
PackAge:As customer request
ProductionCapacity:100|Kilogram|Week
Storage:Store in a cool,dry place and keep away from direct strong light
Transportation:By Sea/Air/Courier

Superiority:

Triumph Chemical Title

Triumph Company Office picture

Triumph Company advantage

Triumph Testing title picture

Triumph Testing way

Details:

Afatinib Irreversible EGFR/HER2 inhibitor CAS# 439081-18-2

[CAS No].850140-72-6

[Chemical Name]:Afatinib

[Molecular Formula]:C24H25ClFN5O3

[Formula Weight]:485.9384032

[Assay]:99%

[Appearance]:white Powder
[Stock]: less than 10kg

[Customer Synthesis] : Availabe

[Package]:100g, 500g, 1kg Foil bag/Bottle

Afatinib(439081-18-2) Chemical Properties,Uses,Production

General Description

Afatinib is a prescription medicine that can be taken orally for the treatment of non-small cell lung cancer (NSCLC) with atypical Epidermal Growth Factor Receptor (EFGR) agents. Afatinib is also prescribed for the treatment of NSCLC with the potential or radiating to other body tissues other than the lungs (metastatic cancer) as detected through an FDA approved examination. Afatinib is a 4-anilinoquinazoline tyrosine kinase suppressor that is available as a dimaleate salt (brand name: Giltrif). The drug is the first FDA-endorsed oncology product by Boehringer Ingelheim.

Indication

The drug is a kinase agonist that is indicated as monotherapy for EFGR and tyrosine kinase suppressor-naive adult patients whose NSCLC is metastatic or locally advanced and the tumours are resistant to EGFR mutations as approved by an FDA-endorsed examination. In addition, the adult patients should indicate signs of squamous histology progress at the time of platinum-based chemotherapy or after the sessions.

Afatinib (BIBW 2992) Chemical Properties

density	1.380
CAS DataBase Reference	439081-18-2

Safety Information

HS Code

29349990

Afatinib (BIBW 2992) Usage And Synthesis

Pharmacological effects

Afatinib (BIBW 2992) is the second-generation potent and irreversible dual inhibitor of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinase, developed by Boehringer Ingelheim, Germany. It is capable of irreversibly inhibiting the activity of the tyrosine kinase by undergoing the Michael reaction with the thiol group of cysteine at position 797 of the EGFR. On July 12, 2013, it became a new drug for anti-small cell lung cancer approved by the US FDA under the trade name of Gilotrif. This drug is a tablet. It is used for the treatment of the patients diagnosed with metastatic non-small cell lung cancer (NSCLC) with the loss of the 19th exon or L858R mutation in the 21th exon of the tumor epidermal growth factor receptor (EGFR) confirmed using the kit approved by FDA. The drug is also effective in the treatment of HER2-positive patients with advanced breast cancer.
Boehringer Ingelheim Pharmaceuticals has applied for the protection of this compound by applying patents JP2004516283 US2010010023 WO2002050043 and so on.
Lung cancer is the world's top tumor killer with the incidence in male being higher than that in women. The number of annually new diagnosed lung cancer patients can reach 1.6 million. However, lung cancer is not just a disease. Studies have shown that lung cancer contains many different types with different types of lung cancer needs to be given specific treatment. A specific subtype of lung cancer can be determined by EGFR (ErbB receptor family members) mutation detection. These patients are also those who can benefit from the most during the treatment with Afatinib in clinical trials.